Table 3.
Univariate and multivariate analysis for PFS and OS according to EGFR mutation status
| Progression‐free survival | Overall survival | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| To chemotherapy among wt‐EGFR | To TKIs among EGFR (+) | To chemotherapy among wt‐EGFR | To TKIs among EGFR (+) | |||||||||||||
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||||
| Median, 95% CI | P‐value | Median, 95% CI | P‐value | Median, 95% CI | P‐value | Median, 95% CI | P‐value | Median, 95% CI | P‐value | Median, 95% CI | P‐value | Median, 95% CI | P‐value | Median, 95% CI | P‐value | |
| Sex | ||||||||||||||||
| Male | 9.7 (1.4‐17.9) | 12.2 (7.9‐16.4) | 19.5 (11.9‐27.2) | 29.2 (20.2‐38.2) | ||||||||||||
| Female | 5.3 (4.0‐6.7) | .102 | 1.6 (0.8‐3.3) | .191 | 7.4 (0.3‐14.5) | .682 | 21.5 (17.5‐25.4) | .071 | 0.8 (0.5‐ 1.3) | .347 | NR(NR) | .603 | ||||
| Age | ||||||||||||||||
| <60 y | 5.2 (3.7‐6.6) | 55.9 (NR) | 28.9 (14.1‐43.9) | NR(NR) | ||||||||||||
| ≥60 y | 6.9 (2.7‐11.3) | .648 | 8.9 (5.2‐12.7) | .027 | 2.4 (0.9‐6.2) | .071 | 20.8 (18.0‐23.5) | .322 | 29.2 (17.6‐40.8) | .111 | 1.3 (0.8‐1.9) | .324 | ||||
| Tobacco exposure | ||||||||||||||||
| Nonsmoker | 5.3 (2.5‐8.1) | 9.7 (4.5‐14.9) | 20.9 (18. 0‐23.8) | NR(NR) | ||||||||||||
| Smoker | 9.4 (3.9‐14.9) | .392 | NR (NR) | .128 | 25.6 (16.9‐34.3) | .862 | 40.3 (NR) | 0.862 | ||||||||
| Wood smoke exposure | ||||||||||||||||
| Absent | 7.9 (3.9‐11.8) | 10.8 (3.5‐18.1) | 20.9 (17.2‐24.7) | 40.3 (39.1‐41.5) | ||||||||||||
| Present | 4.6 (2.1‐7.1) | .063 | 1.9 (1.0‐3.6) | .047 | 9.8 (5.3‐14.2) | .756 | 26.9 (12.8‐40.9) | .648 | 29.2 (20.0‐38.3) | .783 | ||||||
| ECOG PS | ||||||||||||||||
| 0‐1 | 7.2 (3.5‐10.9) | 12.5 (8.9‐16.2) | 26.6 (19.2‐34.1) | 40.3 (26.9‐57.8) | ||||||||||||
| 2+ | 3.0 (2.6‐3.4) | .02 | 2.4 (1.0‐5.3) | .039 | 4.4 (0.9‐7.8) | .002 | 4.4 (1.3‐14.9) | .019 | 15.4 (9.7‐21.1) | .001 | 2.7 (1.4‐5.3) | .002 | 23.1 (14.9‐31.3) | .461 | ||
| Disease Stage | ||||||||||||||||
| IIIB | NR (4.6‐NR) | NR (NR) | NR (NR) | NR(NR) | ||||||||||||
| IV | 5.7 (2.9‐11.1) | .09 | 10.8 (5.7‐NR) | .111 | 20.9 (9.7‐31.2) | .535 | 39.8 (21.5‐NR) | .367 | ||||||||
| Histology | ||||||||||||||||
| Adenocarcinoma | 6.7 (4.6‐8.9) | 10.7 (6.8‐14.7) | 21.5 (9.7‐31.9) | 39.8 (21.5‐NR) | ||||||||||||
| Squamous | 4.7 (1.3‐8.0) | .298 | 14.3 (NR) | .919 | 18.2 (5.2‐NR) | .679 | NR(NR) | .543 | ||||||||
| Histological grade | ||||||||||||||||
| High‐Moderate | 9.4 (6.1‐12.7) | 12.5 (9.2‐15.8) | 23.3 (16.7‐29.8) | 40.3 (23.8‐56.8) | ||||||||||||
| Low | 5.5 (3.2‐7.9) | .119 | 8.6 (7.0‐10.3) | .386 | 14.9 (7.0‐22.8) | .042 | 1.7 (1.1‐ 2.8) | .026 | 39.8 (18.9‐60.6) | .533 | ||||||
| Contralateral lung metastases | ||||||||||||||||
| Absent | 6.9 (3.7‐10.2) | 12.2 (9.7‐14.6) | 20.9 (17.3‐24.6) | 40.3 (26.6‐54.0) | ||||||||||||
| Present | 5.2 (3.9‐6.4) | .525 | 8.3 (4.3‐12.3) | .042 | 20.8 (5.7‐35.9) | .823 | NR(NR) | .204 | ||||||||
| CNS metastases | ||||||||||||||||
| Absent | 6.2 (4.2‐8.2) | 9.7 (6.6‐12.8) | 21.5 (15.9‐27.0) | 29.2 (10.8‐47.6) | ||||||||||||
| Present | 5.0 (1.9‐8.1) | .596 | 15.4 (0.0‐40.9) | .34 | 16.8 (10.1‐23.4) | .667 | NR(NR) | .118 | ||||||||
| Bone metastases | ||||||||||||||||
| Absent | 5.7 (3.9‐7.5) | 10.7 (6.0‐15.4) | 20.8 (16.9‐24.6) | 39.8 (27.8‐51.7) | ||||||||||||
| Present | 3.4 (0.0‐9.8) | .475 | 6.8 (2.0‐11.6) | .162 | 22.1 (8.8‐35.4) | .993 | NR(NR) | .979 | ||||||||
| CEA | ||||||||||||||||
| <5 pg/mL | 9.4 (2.9‐15.8) | 10.8 (7.7‐13.9) | 36.9 (4.2‐69.5) | 29.2 (NR) | ||||||||||||
| ≥5 pg/mL | 5.3 (2.9‐7.7) | .267 | 10.7 (3.2‐18.3) | .81 | 20.9 (17.2‐24.7) | .521 | 40.3 (18.6‐62.0) | .755 | ||||||||
| CD47 | ||||||||||||||||
| Absent | 5.7 (4.7‐6.7) | NC | 20.0 (7.1‐32.9) | NR(NR) | ||||||||||||
| Present | 6.7 (4.3‐9.2) | .843 | NC | 20.0 (17.2 −24.7) | .928 | 39.8 (17.2‐63.4) | .452 | |||||||||
| CD47 score | ||||||||||||||||
| <150 | 5.7 (3.6 −7.8) | NR (NR) | 20.8 (16.5‐25.1) | NR(NR) | ||||||||||||
| ≥150 | 6.2 (0.5‐11.9) | .59 | 10.7 (7.9‐13.5) | .156 | 23.9 (15.5‐32.4) | .545 | 29.2 (15.7‐42.6) | .023 | 1.3 (0.8‐2.0) | .31 | ||||||
Abbreviations: CEA, Carcinoembryonic antigen; CI, Confidence interval; CNS, Central Nervous System; ECOG PS, Eastern cooperative oncology group performance status; EGFR, Epidermal Growth Factor; HR: Hazard ratio; NR, Not reach.